The North America Biosimilars Market would witness market growth of 23.6% CAGR during the forecast period (2022-2028).
Biosimilars are rigorously and thoroughly examined by the FDA before approval, and they are just as secure and efficient as the original biologic. Before approving a biosimilar, FDA experts must determine if it is extremely similar to the original biologic and doesn't differ from it in any way that would have clinical significance. All biosimilar products must meet the FDA's stringent conditions for approval and undergo a thorough evaluation by the agency to ensure they are equally safe & effective as their reference products. This implies that throughout the course of treatment, the biosimilar will be as safe and effective as the original product. The FDA also strictly controls the production of biosimilars. The biosimilar is subject to the same high manufacturing standards as the original biologic.
Biosimilars may increase patient access to advanced drug therapies and reduce the financial burden that chronic diseases place on the world's healthcare systems. To achieve this, however, it is necessary for doctors to feel more at ease prescribing biosimilars as opposed to their reference products, and biosimilars' costs must be significantly lower than those of their biological counterparts.
In the United States, 1,752,735 new cases of cancer were reported in 2019, and 599,589 people passed away from the disease. In addition to helping to enhance the health of individuals in low- and middle-income countries, the US government's healthcare initiatives seek to support the country's larger development goals, foreign policy priorities, and national security concerns. The United States is currently the top financier & implementer of health initiatives worldwide since it started taking part in them more than a century ago. These initiatives are supported by numerous US government departments and agencies, congressional committees, and funding sources.
The US market dominated the North America Biosimilars Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $15,999.6 million by 2028. The Canada market is estimated to grow at a CAGR of 26.4% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 25.3% during (2022 - 2028).
Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Biosimilars Market is Estimated to reach $59 Billion by 2028, at a CAGR of 24.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Scope of the Study
Market Segments Covered in the Report:
By Application
- Oncology Diseases
- Blood Disorders
- Chronic & Autoimmune Diseases
- Others
By Type
- Monoclonal Antibodies
- Granulocyte-Colony Stimulating Factor
- Erythropoietin
- Human Growth Hormone
- Insulin
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Biosimilars Market, by Application
1.4.2 North America Biosimilars Market, by Type
1.4.3 North America Biosimilars Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jun – 2022, Aug) Leading Players
Chapter 4. North America Biosimilars Market by Application
4.1 North America Oncology Diseases Market by Country
4.2 North America Blood Disorders Market by Country
4.3 North America Chronic & Autoimmune Diseases Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Biosimilars Market by Type
5.1 North America Monoclonal Antibodies Market by Country
5.2 North America Granulocyte-Colony Stimulating Factor Market by Country
5.3 North America Erythropoietin Market by Country
5.4 North America Human Growth Hormone Market by Country
5.5 North America Insulin Market by Country
5.6 North America Others Market by Country
Chapter 6. North America Biosimilars Market by Country
6.1 US Biosimilars Market
6.1.1 US Biosimilars Market by Application
6.1.2 US Biosimilars Market by Type
6.2 Canada Biosimilars Market
6.2.1 Canada Biosimilars Market by Application
6.2.2 Canada Biosimilars Market by Type
6.3 Mexico Biosimilars Market
6.3.1 Mexico Biosimilars Market by Application
6.3.2 Mexico Biosimilars Market by Type
6.4 Rest of North America Biosimilars Market
6.4.1 Rest of North America Biosimilars Market by Application
6.4.2 Rest of North America Biosimilars Market by Type
Chapter 7. Company Profiles
7.1 Fresenius SE & Co. KGaA
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Product Launches and Product Expansions:
7.1.5.3 Acquisition and Mergers:
7.2 Dr. Reddy’s Laboratories Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Product Launches and Product Expansions:
7.3.5.3 Acquisition and Mergers:
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Product Launches and Product Expansions:
7.4.5.3 Acquisition and Mergers:
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Approvals and Trials:
7.5.5.3 Product Launches and Product Expansions:
7.6 Eli Lilly And Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Merck & Co., Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.8 Novartis AG (Sandoz)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.9 Biocon Limited
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Partnerships, Collaborations, and Agreements:
7.9.2.2 Product Launches and Product Expansions:
7.9.2.3 Acquisition and Mergers:
7.10. Intas Pharmaceutical Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
7.10.2.2 Product Launches and Product Expansions:
TABLE 1 North America Biosimilars Market, 2018 - 2021, USD Million
TABLE 2 North America Biosimilars Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Biosimilars Market
TABLE 4 Product Launches And Product Expansions– Biosimilars Market
TABLE 5 Acquisition and Mergers– Biosimilars Market
TABLE 6 Approvals and Trials – Biosimilars Market
TABLE 7 North America Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 8 North America Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 9 North America Oncology Diseases Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Oncology Diseases Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Blood Disorders Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Blood Disorders Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 18 North America Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 19 North America Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Erythropoietin Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Erythropoietin Market by Country, 2022 - 2028, USD Million
TABLE 25 North America Human Growth Hormone Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Human Growth Hormone Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Insulin Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Insulin Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 31 North America Biosimilars Market by Country, 2018 - 2021, USD Million
TABLE 32 North America Biosimilars Market by Country, 2022 - 2028, USD Million
TABLE 33 US Biosimilars Market, 2018 - 2021, USD Million
TABLE 34 US Biosimilars Market, 2022 - 2028, USD Million
TABLE 35 US Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 36 US Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 37 US Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 38 US Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 39 Canada Biosimilars Market, 2018 - 2021, USD Million
TABLE 40 Canada Biosimilars Market, 2022 - 2028, USD Million
TABLE 41 Canada Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 42 Canada Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 43 Canada Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 44 Canada Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 45 Mexico Biosimilars Market, 2018 - 2021, USD Million
TABLE 46 Mexico Biosimilars Market, 2022 - 2028, USD Million
TABLE 47 Mexico Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 48 Mexico Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 49 Mexico Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 50 Mexico Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 51 Rest of North America Biosimilars Market, 2018 - 2021, USD Million
TABLE 52 Rest of North America Biosimilars Market, 2022 - 2028, USD Million
TABLE 53 Rest of North America Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 54 Rest of North America Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 55 Rest of North America Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 56 Rest of North America Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 57 key information – Fresenius SE & Co. KGaA
TABLE 58 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 59 Key Information – Pfizer, Inc.
TABLE 60 Key Information – Amgen, Inc.
TABLE 61 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 62 Key Information – Eli Lilly And Company
TABLE 63 KEY INFORMATION - MERCK & CO., INC.
TABLE 64 Key Information – Novartis AG
TABLE 65 Key Information – Biocon Limited
TABLE 66 Key Information – Intas Pharmaceutical Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jan – 2022, Aug) Leading Players
FIG 5 Recent strategies and developments: Fresenius SE & Co. KGaA
FIG 6 Recent strategies and developments: Dr. Reddy’s Laboratories Ltd.
FIG 7 Recent strategies and developments: Pfizer, Inc.
FIG 8 Recent strategies and developments: Amgen, Inc.
FIG 9 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 10 Recent strategies and developments: Novartis AG
FIG 11 Recent strategies and developments: Biocon Limited
FIG 12 Recent strategies and developments: Intas Pharmaceutical Ltd.